Discuss the significance of India's expanding 'vigilance' ecosystem (pharmacovigilance, materiovigilance, biovigilance) in strengthening patient safety. What institutional gaps remain?

India's post-market safety architecture has widened from medicines (Pharmacovigilance Programme of India, 2010) to devices (materiovigilance), and now to transplants and biologicals through the Biovigilance Programme of India (BvPI), announced on 21 September 2026 alongside the 7th National Formulary of India [1]. The expansion is significant, yet institutionally incomplete.

Significance for patient safety

• Closes a real monitoring gap: organ transplants have quadrupled, from under 5,000 in 2013 to over 20,000 in 2025 [5], yet post-transplant adverse events had no national reporting vertical, since PvPI covers only adverse drug reactions [2].
• Single nodal architecture: the Indian Pharmacopoeia Commission, a statutory body under MoHFW, hosts the National Coordinating Centre and now anchors all three verticals [2], reducing coordination gaps between the regulator (CDSCO) and hospitals.
• Global credibility: NCC-PvPI was recognised as a WHO Collaborating Centre (2017) — the first globally on this theme [2] — a template BvPI can inherit.
• Rational prescribing: the NFI, published by IPC since 2008, guides evidence-based prescribing [3]; its digital edition extends it as a clinical decision-support tool [1].

Institutional gaps that remain

• Voluntary reporting culture: sixteen years on, PvPI still relies on annual awareness drives — the 2025 theme was "Your Safety, Just a Click Away: Report to PvPI" [4] — and no statutory reporting duty accompanies BvPI's announcement [1].
• Traceability deficit: organs are retrieved in one hospital and implanted in another; without a shared donor identifier linking IPC's reporting to the NOTTO network [5], harm from a single donor to multiple recipients escapes detection.
• Short follow-up horizon: donor-origin infection or malignancy surfaces late, so one-time surgical forms will miss precisely what BvPI exists to catch.
• Reporter protection: confidential, blame-free reporting and structured feedback to reporting hospitals are not yet institutionalised.

Together, these verticals mark a shift from regulating product quality to tracking real-world harm. Attaching a mandatory reporting duty under the Transplantation of Human Organs and Tissues Act, 1994, sharing a unique donor-recipient identifier with NOTTO, and returning findings to reporters would convert announcement into assurance — strengthening the quality-of-care pillar of universal health coverage.